CN113403274B - 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用 - Google Patents
细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用 Download PDFInfo
- Publication number
- CN113403274B CN113403274B CN202110722210.1A CN202110722210A CN113403274B CN 113403274 B CN113403274 B CN 113403274B CN 202110722210 A CN202110722210 A CN 202110722210A CN 113403274 B CN113403274 B CN 113403274B
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- ige
- cik
- msc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 title abstract description 18
- 208000023275 Autoimmune disease Diseases 0.000 title abstract description 11
- 208000030961 allergic reaction Diseases 0.000 title abstract description 7
- 229940126585 therapeutic drug Drugs 0.000 title description 2
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 138
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 238000003501 co-culture Methods 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 6
- 238000002659 cell therapy Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 238000012258 culturing Methods 0.000 abstract description 10
- 230000002349 favourable effect Effects 0.000 abstract description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 19
- 208000026935 allergic disease Diseases 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 208000009329 Graft vs Host Disease Diseases 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000002303 tibia Anatomy 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 241001412225 Firmiana simplex Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940046536 tree pollen allergenic extract Drugs 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 108010084455 Zeocin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000003954 umbilical cord Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000024340 acute graft versus host disease Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000919 anti-host Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960004784 allergens Drugs 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- -1 i.e. Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 208000006455 storm syndrome Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/137—Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供了一种细胞治疗组合物，将I gE(CH3)DC与CI K细胞共培养得到的I gE(CH3)DC‑CI K细胞，再与同种异体MSC细胞共培养制备得到细胞治疗组合物，本发明还提供了一种上述细胞治疗组合物在制备用于治疗过敏性反应及自身免疫疾病的细胞类药物中的应用。本发明运用I gE(CH3)DCCI K+MSCs共培养细胞治疗过敏性反应及自身免疫疾病，通过实验证明会产生更为有利的结果，且不具有任何副作用。
Description
技术领域
本发明涉及细胞免疫领域，具体涉及一种细胞治疗组合物及其制备方法和用于治疗过敏性反应及自身免疫疾病的用途。
背景技术
目前治疗过敏性反应，比如过敏性哮喘，主要使用糖皮质激素类广谱免疫抑制剂。该类药物虽然对过敏性反应的控制有一定效果，但由于对大多数免疫细胞均有抑制作用，所以副作用明显，如长期使用会导致机体免疫功能低下，易诱发感染、肿瘤等疾病。
因此，如何研发一种没有副作用或副作用较小的过敏性反应治疗药物，一直是本领域技术人员致力于开发的方向之一。
发明内容
本发明的目的，就是为了解决上述问题而提供了一种细胞治疗组合物及其制备方法，该细胞治疗组合物能有效治疗过敏源引起的***反应性疾病及急性转移植物抗宿主病乃至目前流行性新冠病，且不具有任何副作用。
本发明的目的是这样实现的：
本发明提供了一种细胞治疗组合物，包括治疗有效量的DC细胞、CIK细胞和MSC细胞。
上述的细胞治疗组合物，其中，所述DC细胞和CIK细胞为自体细胞，所述MSC细胞为同种异体细胞,且所述DC细胞携带IgE的CH3蛋白片段。
本发明还提供了一种细胞治疗组合物的制备方法，包括以下步骤：
(1)自体外周血单个核细胞的制备；
(2)DC细胞的分离和培养；
(3)CIK细胞的诱导培养；
(4)DC细胞中加入IgE的CH3蛋白片段，制备IgE(CH3)DC细胞；
(5)IgE(CH3)DC细胞与CIK细胞共培养，制备IgE(CH3)DC-CIK细胞；
(6)IgE(CH3)DC-CIK细胞与同种异体MSC细胞共培养制备细胞治疗组合物。
上述的一种细胞治疗组合物的制备方法，其中，步骤(4)中，所述CH3蛋白片段的浓度为50ug-500ug/1×107DC细胞。
上述的一种细胞治疗组合物的制备方法，其中，步骤(4)中，所述CH3蛋白片段采用真核细胞基因表达得到。
上述的一种细胞治疗组合物的制备方法，其中，步骤(5)中，IgE(CH3)DC细胞与CIK细胞按照1:3-5的细胞数量比例混合共培养。
上述的一种细胞治疗组合物的制备方法，其中，步骤(6)中，MSC细胞与IgE(CH3)DC-CIK细胞按照1:10-50的细胞数量比例混合共培养。
上述IgE(CH3)DC-CIK细胞与MSC细胞共培养得到的细胞治疗组合物可作为治疗过敏性反应及自身免疫疾病的细胞类药物。
IgE(CH3)基因表达后糖基化与DC细胞上甘露糖受体结合，与CIK共培养，DC是专职呈递细胞，DC与IgE(CH3)识别递呈再与CIK共培养可促进CIK的增殖，同时CIK细胞对DC的成熟也有促进作用，这些功能是通过DC与CIK分泌互补的细胞因子来完成。在IgE(CH3)DC与CIK共培养过程中激发CIK的细胞活性，使CIK等T杀伤细胞赋予IgE(CH3)的记忆性，在机体内清除病源体细胞，降低***反应性疾病的发生，即为细胞介导的细胞免疫效应。
DC在培养过程中内化携带IgE(CH3)，激活DC细胞的MHCⅡ分子，形成复合物，然后递呈予Th细胞，在体内激活的Th细胞通过信号分子识别B细胞，引起B细胞增殖、抗体的产生以及抗体类别的转换，为B细胞介导的体液免疫效应。
本发明在选择MSC细胞与IgE(CH3)DC-CIK细胞再共培养，在IgE(CH3)DC-CIK的培养体系的特定的微环境中，MSC通过共培养的细胞间的接触、内化作用，可分泌多细胞因子，特别是分泌一种倾化因子可训化共培养条件下的T效应细胞，使其在特定的培养条件被诱导分化成不同表型特征的细胞，注入体内可更有效地清除分泌IgE或结合IgE(CH3)的病源体细胞。
MSC(人脐带间充质干细胞)本身是一种早期不表达MHC基因且对免疫***有良好的调节作用，很多实验证明MSC是治疗过敏源引起的***反应性疾病及急性转移植物抗宿主病乃至目前流行性新冠病均已取得良好结果。
本发明涉及对***反应性疾病：①T细胞免疫效应；②DC呈递CH3抗原产生的细胞免疫效应；③MSCS单项免疫调节效应及其MSC与上述DCCIK细胞的协同、连动功能性效应。本发明运用IgE(CH3)DCCIK+MSCs共培养细胞治疗过敏性反应及自身免疫疾病，通过实验证明会产生更为有利的结果，且不具有任何副作用。
具体实施方式
下面结合具体实施例对本发明作进一步的说明，但并不局限于此。下述实施例中所述试剂原料除非注明来源外，均为市售的常见原料，试剂的配制采用常规方法。实施例中未详述的方法均为本领域常规操作。
发明中的实施例均选用SD大鼠作为验证实验动物。
实施例1：全基因组PCR获取IgE的CH3基因片段并构建重组质粒
合成PCR两对引物P1和P2。引物P1和P2的5’端和3’端的酶切位点分别引入EcoRⅤ和EcoRⅠ酶切位点，以构建pVAC-CH3重组质粒。
P1:5’-GGGATATCATGCCGACAGATCATGAGCCACG-3’(下划线部分为EcoRⅤ酶切位点)
P2:5’-GGGAATTCTCACTGGGGAAGGGTGATGGAAC-3’(下划线部分为EcoRⅠ酶切位点)
以SD大鼠全基因组DNA为模板，建立100μL的反应体系，包括10×PCR反应缓冲液10μL、25mMMgCl26μL、DMSO5Μl、dNTP8μL、上下游引物各4μL、大鼠全基因组DNA 4μL和水60μL。然后进行PCR反应，95℃预变性5min后加入TaqDNA聚合酶3.2μL。反应条件为：94℃变性1min，56℃退火1min，72℃延伸2min，共进行39个循环。最后一个循环72℃延伸10min，4℃保存。
重组质粒pVAC-CH3的构建
以全基因组DNA为模板，应用引物P1、P2扩增出IgE的CH3片段，连入PMD18-Tvector，用EcoRⅠ和EcoRⅤ双酶切T-CH3，回收的小片段与pVAC空载体双酶切回收的大片段进行连接。连接产物转化感受态细胞DH5α，zeocin抗双素筛选，挑取阳性克隆，于LB培养基中培养过夜，提取质粒DNA，经酶切鉴定和DNA序列分析，将测序正确者命名为pVAC-CH3。
重组质粒的扩增
重组质粒pVAC-CH3，转化感受态细胞DH5α，培养过夜，次日清晨挑取单克隆，接种于10mL含zeocin抗生素的LB培养基中培养8h，再按1:100的比例接种于300mL含zeocin抗生素的LB培养基，37℃摇菌2.5h，于37℃剧烈振荡再培养16h。
重组质粒的大量提取及纯化
用合适转头于4℃以4100rpm离心20min，弃上清收菌，将细菌沉淀重悬于50mL用冰预冷的STE中，洗涤一次，弃上清。将细菌沉淀物重悬于10mL溶液Ⅰ中，加1mL新配制的溶菌酶溶液，再加20mL新配制的溶液Ⅱ，盖紧瓶盖，缓缓颠倒离心瓶数次，充分混匀内容物，于室温放置5-10min。加15mL用冰预冷的溶液Ⅲ。封住瓶口，摇动离心瓶数次以混匀内容物。置冰上放10min，应形成一白色絮状沉淀。
用合适转头于4℃以11000rpm离心30min，使转头自然停转。小心将上清全部转到另一瓶中，弃去离心管中的沉淀。量取上清的体积，将其连同0.6倍体积的异丙酮一起移入一只洁净离心管中充分混匀，室温下放置10min。在室温下以8000rmp离心15min，回收核酸沉淀。小心倒掉上清，将离心管敞开盖，倒置于纸巾上以除去残余的上清。室温用70％乙醇洗涤沉积管底及管壁。倒出乙醇，用与真空装置相联的巴斯德吸管吸出附于瓶壁的所有液滴，将离心管开口倒置于纸巾上，使残余的痕量乙醇挥发殆尽，用2mLTE(pH8.0)溶解核酸沉淀。用酚、酚：氯仿、氯仿各抽1次纯化质粒。用TE(pH8.0)将核酸沉淀1:100稀释后测量OD260/OD280，计算质粒DNA的浓度(1OD260＝50μg质粒DNA/mL)，将提取的质粒单酶切后进行琼脂糖电泳检测效果，然后将DNA贮于-20℃。
实施例2：CH3蛋白片段的真核表达、提取及纯化
将生长状态良好的CHO细泡，以每孔1×105个接种于6孔板中，待细胞完全贴壁生长至80％时，用无血清无抗生素的RPMI 1640培养液洗涤细胞2次。取2μgDNA溶于100μL无血清无抗生素RPMI 1640培养液中，称为A液。将10μLLiopfectAMINETM2000溶于90μL无血清无抗生素RPMI 1640培养液中，放置10min，称为B液。将A、B两液混合，室温孵育30min，使其形成DNA-liposome复合物。在复合物中加入800μL无血清无抗生素的DMEM培养液，轻轻混匀，缓缓滴加至洗过的细胞中，与于37℃CO2孵箱中培养6h。吸弃转染液，加入1mL含20％小牛血清的无抗生素RPMI 1640培养液继续培养，转染48h后收集细胞进行目的蛋白瞬时表达的检测，筛选得到转染并成功表达的CHO细胞。
通过CHO细胞真核表达，最终提取及纯化得到CH3蛋白片段备用。
实施例3：梧桐花粉浸出液的制备
梧桐花粉是常见的过敏原，常会诱发支气管哮喘、过敏性鼻炎等***反应性疾病，在花粉症患者血清中存在特异性IgE，在血液中IgE含量的波动性大、稳定性差，所以为本实验的正确性建立IgE分泌稳定的实验动物模型，我们用国内常见的SD大鼠，其过敏反应与人类相似，也是由IgE介导研究人类***反应疾病机制与治疗的关系。
梧桐花粉自然干燥至恒重，用***脱脂数次直至***层无色，***彻底挥发后按每克花粉加入10mLCOCa’s(5.0g氯化钠、2.75g碳酸氢钠、4mL苯酚，加蒸馏水至1000mL)溶液的比值(1:10，w/v)。于4℃浸出48h，期间用磁力搅拌几次，每次20min，浸出后离心取出上清液，其蛋白质含量在1mg/mL左右，此浸出液置透析袋中用PBS透析至外液无色，梧桐浸出液经无菌过滤后分装、冻存。
实施例4：SD大鼠MSC细胞的制备
健康6只-10只SD大鼠(200g/只)雌雄不限，真空处死，75％乙醇浸泡5min无菌超净工作台大鼠双侧股骨、胫骨。无菌剪剥离肌肉，将分离干净的股骨、胫骨放入PBS液中，大号剪剪开股骨、胫骨，用1mL无菌注射器吸取PBS液反复冲洗股骨、胫骨骨髓腔，然后吸出置10mL离心管中以400×g离心5min，弃上清液，计数辅24孔板，MSC 3×104/孔1mLMSC培养液(友康)放入37℃，5％CO2饱和湿度的细泡培养箱中培养。
实施例5：IgE(CH3)DC-CIK+MSC共培养细胞的制备
采用SD大鼠(实验组)尾静脉分别抽血(或开胸心脏采血)，采血后制备SD大鼠过敏模型(包括制备阴性对照血清取样保存)。本实验要求同种异MSC，自体DCCIK。
将新鲜分离的血液成分400g离心10分钟后，去除上层血浆成分。
剩余血液中等倍加入0.9％生理盐水注射液，轻轻混匀。
在15ml离心管中加入5ml淋巴细胞分离液，在其上层缓缓滴入血液及生理盐水混合液约5ml，400g离心20分钟。
将分层后的白细胞层液体轻轻吸出，置于新的离心管中，加入一定量的生理盐水,轻轻混匀后，400g离心10分钟。
去除上清液，再补充新的生理盐水，轻轻混匀后，400g离心10分钟。
去除上清液，再补充新的生理盐水。
算收率及存活率：吸取100ul细胞悬液，加入等体积0.2％台盼兰，混合均匀。用血球计数板计总细胞的数量，计算总细胞密度，同时计活细胞数量，计算活细胞密度。该法重复三次，分别取平均密度，根据接种悬液体积换算出收获的细胞量，并以活细胞数与总细胞数相比得到存活率。
将外周血单个核细胞悬液400g离心10分钟后，去除上清液。
细胞用DCCIK细胞基础培养基即无血清培养基重新悬浮，按照1×105个细胞/ml的接种密度将细胞接种于细胞6培养板中，置于37℃、5％CO2饱和湿度培养箱静置培养3小时。
轻轻摇动细胞培养瓶，将悬浮细胞取出后，转移至新的培养瓶中，并添加IFN-γ1000U/ml,置于37℃、5％CO2饱和湿度培养箱，诱导培养CIK细胞。
原细胞培养瓶中补加DCCIK基础培养基，并添加GM-CSF 1000IU/ml及IL-4 500IU/ml，置于37℃、5％CO2饱和湿度培养箱，诱导培养DC细胞。
次日，CIK细胞培养瓶中添加CD3单抗100ng/ml和IL-2 1000U/ml，置于孔37℃、5％CO2饱和湿度培养箱静置培养。每2-3天添加新鲜培养液无血清培养基+IL-2 500U/ml并传代。
次日DC细胞中加入CH3基因表达的蛋白片段。CH3蛋白片段浓度按50ug-500ug/1×107DC细胞。
第3日，DC细胞中按照培养基的量及上述浓度补加GM-CSF及IL-4等两种细胞因子，继续诱导培养DC细胞，得到IgE(CH3)DC细胞。
第5日，IgE(CH3)DC细胞中按照培养基的量添加TNF-α200IU/ml，置于37℃、5％CO2饱和湿度培养箱静置48小时，诱导IgE(CH3)DC细胞成熟。
第7日，分别收集IgE(CH3)DC细胞及CIK细胞并计数，按照IgE(CH3)DC细胞:CIK细胞为1:3-5的细胞数量比例将两种细胞混合后，补充新鲜的无血清培养基+IL-2 500U/ml，调整细胞密度约3～5×106个细胞/ml，转移至新的培养瓶中，置于37℃、5％CO2饱和湿度培养箱，共培养IgE(CH3)DC细胞与CIK细胞，
每3天添加新鲜无血清培养基+IL-2 500U/ml，并根据细胞增殖情况传代。
第10-12天将上述IgE(CH3)DC-CIK细胞转移到培养SD大鼠干细胞MSC(P3)的培养瓶。MSC细胞与IgE(CH3)DC-CIK细胞按照1:10-50的细胞数量比例混合，共培养37C 5％饱和温度静置培养。
共培养72小时后将共培养细胞200g离心5分钟，去除上清液，生理盐水洗2次(200g*5分钟)，通过细胞计数，按照IgE(CH3)DC-CIK+MSC共培养细胞1×107的数量备用于过敏模型鼠进行静脉注射。
实施例6：SD大鼠过敏模型实验设计
将5只正常SD大鼠(未过敏刺激)抽血少许作为阴性血清样品保存，第三天用梧桐花粉浸出液(过敏源)1mg/ml取2ml用于SD大鼠皮下多点注射免疫，每周一次，免疫三周后用雾化浸出液冻干粉激发后隔天后尾静脉取样阳性血清样品保存，由此得到了建立了***反应性疾病的SD大鼠动物实验模型。
用实施例5中制备的IgE(CH3)DC-CIK+MSC细胞共培养的细胞，对五只过敏模型SD大鼠分别尾静脉注射每天注射一次，每次使用1×107个细胞(细胞计数)，连续三天，隔四天后尾静脉采血制备血清作为实验组血清(保存)。
实施例7:IgE酶联免疫分析
应用双抗原夹心法测定样品中SD大鼠IgE的浓度：用纯化的抗原包被微孔板，制成固相抗原，往包被的微孔中依次加入免疫球蛋白E(IgE)，再与HRP标记的抗原结合，形成抗原-抗体-酶标抗原复合物，经过彻底洗涤后加底物TMB显色。TMB在HRP酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的免疫球蛋白E(IgE)呈正相关。用酶标仪在450nm波长下测定吸光度(OD值)，通过标准曲线计算样品中人免疫球蛋白E(IgE)浓度。
| 1 | 30倍浓缩洗涤液 | 20ml×1瓶 | 7 | 终止液 | 6ml×1瓶 |
| 2 | 酶标试剂 | 6ml×1瓶 | 8 | 标准液(8μg/ml) | 0.5ml×1瓶 |
| 3 | 酶标包被板 | 12孔×8条 | 9 | 标准品稀释液 | 1.5ml×1瓶 |
| 4 | 样品稀释液 | 6ml×1瓶 | 10 | 说明书 | 1份 |
| 5 | 显色剂A液 | 6ml×1瓶 | 11 | 封板膜 | 2张 |
| 6 | 显色剂B液 | 6ml×1瓶 | 12 | 密封袋 | 1个 |
操作步骤：
A、标准品的稀释：提供原倍标准品一支，按照下列图表在小试管中进行稀释。
| IgE标准品含量 | 稀释 | OD450nn | |
| 3μg/ml | 5号标准品 | 150μl的原倍标准品加入150μl标准品稀释液 | 2.42 |
| 1.5μg/ml | 4号标准品 | 150μl的5号标准品加入150μl标准品稀释液 | 2.16 |
| 0.5μg/ml | 3号标准品 | 150μl的4号标准品加入150μl标准品稀释液 | 1.85 |
| 0.2μg/ml | 2号标准品 | 150μl的3号标准品加入150μl标准品稀释液 | 1.55 |
| 0.1μg/ml | 1号标准品 | 150μl的2－号7－标准品加入150μl标准品稀释液 | 0.90 |
IgE标准品含量制备定量标准曲线
将上述实例6与7中取样保存血清，将上述三种保存血清样本分别同步检测。
B、SD大鼠尾静脉取血：分别为阴性样品(非致敏)5份、阳性血清(致敏)5份、实验组血清(MSC-FC DCCIK)5份,分别设空白孔(空白对照孔不加样品及酶标试剂，其余步骤相同)、标准孔、待测样品孔。在酶标包被板上标准品准确加样50μl，待测样品孔中先加样品稀释液25μl，即为样品的实际浓度。
Elisa检测SD大鼠(阴性、阳性与实验组)血清中IgE的含量：
| 实验分组 | 1号 | 2号 | 3号 | 4号 | 5号 |
| 空白 | 0.07 | 0.069 | 0.090 | 0.059 | 0.089 |
| 阴性血清 | 0.092 | 0.102 | 0.089 | 0.141 | 0.150 |
| 阳性血清 | 1.83 | 1.79 | 2.01 | 2.10 | 1.99 |
| 实验组血清 | 0.202 | 0.353 | 0.26 | 0.30 | 0.25 |
与标准样品曲线查阅比较发现：本发明运用IgE(CH3)DC-CIK+MSC共培养细胞治疗过敏性反应及自身免疫疾病，会产生更为有利的结果，且不具有任何副作用。
IgE是人类多种***反应性疾病的相关分子，Ⅰ型***反应性疾病包括支气管哮喘过敏性鼻炎、特应性皮炎及食物过敏、环境过敏等，在过去的近10年中过敏发病率逐渐上升，全世界约2亿人患有***反应性疾病，估计全球为了防治***反应性疾病从经济代价已远超过用于结核病和艾滋病的总和。目前全世界流行新型性新冠病感染引起的宿主T细胞炎症因子及B细胞增殖分化和相关因子，伴随患者IgE骤然大幅度升高形成为细胞因子风暴的综合征(Cytokin Storm Syndrome，CSS)。
MSCS主要在过敏及炎症环境下产生大量的免疫调节因子，细胞倾化因子和生长因子调节免疫过敏反应，同时MSC亦可促使原位组织干细胞增生，促进组织修复。MSCS治疗急性移植物抗宿主病(aGVHD)，抑制过度的T细胞增殖下调促炎细胞因子和平抑IgE过度升高的引起严重皮疹反应。
LeBlane论述：人脐带间充质干细胞(human umbilical cord,MSC,hUCMSCS)是一群具有支持恢复造血重建，向多种组织细胞分化的多潜能细胞，且尚有低免疫原性及免疫调节的作用，有效减轻GVHD的症状。MSCS与DC-CIK分别与造血干细胞联合移植有协同作用，SAya-lian等论文：通过流式细胞技术(FCM)检测hMSCS与DC-CIK细胞以1:10共培养4d的培养上清中，Th1、Th2细胞因子含量与MSC的免疫调节机制的关联性。Nishimura等“论著hMSC对异体DC-CIK细胞分子影响”，观察到接受异体骨髓细胞移植联合CIK细胞治疗的小鼠全部存活，仅出现轻微的慢性亚临床移植抗宿主病(GVHD)，但输注IFN-r基因敲出的CIK细胞则出现致死性的GVHD，说明CIK减轻GVHD症状与IFN-r相关，而DC-CIK细胞群是以CIK为主的细胞，可见对GVHD有显著作用。
IgE可严重引起自身免疫性疾病，是由于自身免疫耐受被打破，T细胞和抗体与自身的细胞及组织抗原发生反应导致组织的功能丧失或受限，从而产生的慢性炎症性疾病，但目前自身免疫耐受被打破的机制尚未明确。自身性疾病Ⅰ型糖尿症、类风湿关节炎、红斑狼疮多发性硬化、重症肌无力。现在治疗自身的免疫疾病抑制全身性免疫***，从而增加患者感染与肿瘤疾病的产生，而采用MSC-IgE(CH3)DCCIK可能有很好的结果。
本发明运用IgE(CH3)DCCIK+MSCs共培养细胞治疗过敏性反应及自身免疫疾病预期会产生更为有利的结果，DC递呈IgE(CH3)与CIK共培养中加入MSC再共培养，细胞与细胞之间的接触作用，引起胞质膜的直接接触并产生细胞外基质(ECM)，干细胞分化受到细胞外基质的影响，不少干细胞位于细胞外基质之中，而后者往往就是干细胞与其子细胞的产物在不同体外培养环境或体内组织中其基质有不同的结构特征，产生蛋白多糖及粘黏蛋白等引起细胞之间的互动，其中MSCs分泌的趋化因子、训化功能，如训化CIK细胞及CD8 +T细胞等。有关文献报导MSCs与DC-CIK共培养涉及细胞生物学与分子生物学的相关理论。
有学者认为MSCs免疫调节的作用机制尚不完全清楚，实验证明细胞接触或间接接触是通过MSCs分泌的可溶性细胞因子如：TGF-β、PGE2等有关，Meisel等认为与MSC在IFN-r刺激后活化吲哚胺2,3双加氧酶(IDO)有关，Aggarwal报道MSC使Th1细胞分泌IFN-r减少，而Th2细胞分泌IL-4增加。栾希英报道MSCs抑制PHA活化的淋巴细胞分泌IFN-r、IL-2。也有文献报导MSCs促进新鲜分离的淋巴细胞分泌IL-2、IL-10，文献报导MSCs与DCCIK共培养发现Th1类细胞因子与Th2类细胞因子及Th1与Th2因子的互相转换-MSCs与致敏DCCIK共培养主要会产生细胞免疫，当前的一些研究结果MSC存在某种细胞被诱导分化成功能细胞乃至修复组织器官功能，整个发生过程中会顺应该微环境中细胞发生的方向，其中充分地表现干细胞的作用，在IgE(CH3)DC+CIK的共培养中，MSC通过各种细胞因子的传导促成T细胞清除，IgE的病源细胞及阻断IgE致敏途径。
DC细胞是免疫***中的抗原呈递细胞(Antigen Presenting Cell，APC)，DC细胞吞饮抗原或摄取DC受体介导抗原，然后将抗原加工处理、降解为多肽片段，并与MHC分子结合形成MHC分子复合物，转移至DC表面并与T细胞表面TCR结合将抗原肽呈递给CD4 +T细胞其过程按MHC-1类分子结合或以MHCⅡ类分子途径呈递，呈递方式抗原的来源决定。体外诱导扩增DCCIK细胞属细胞免疫效应，CIK是一种新型的免疫活性细胞，DC细胞与CIK共培养是细胞免疫治疗的两个重要部分。前者识别抗原，激活获得性免疫***，后者通过DC信号传递发挥其自身细胞毒效应和分泌大量细胞因子去清除病源性细胞(包括Cancer Cell)。
DC与CIK细胞共培养时两者相互调节，CIK细胞能促DC的成熟同时DC细胞能增强CIK细胞的增殖能力和杀伤活性。举例：IgE(CH3)DC与CIK共培养，DC表面标记CD80；CD86；CD40人白细胞抗原表达增加。DC递呈IgE(CH3)抗原过程，分泌细胞因子IL-1α、IL-8、TNF-α、INF-α和GM-CSF等发挥调节作用，DC分泌的趋化因子介导与激活CIK细胞。DC也可以激活不同亚类的T细胞，使Th细胞向不同方向分化，从而诱导B细胞免疫应答。
以上实施例仅供说明本发明之用，而非对本发明的限制，有关技术领域的技术人员，在不脱离本发明的精神和范围的情况下，还可以作出各种变换或变型，因此所有等同的技术方案也应该属于本发明的范畴，应由各权利要求所限定。
Claims (7)
1.一种细胞治疗组合物，其特征在于，包括治疗有效量的DC细胞、CIK细胞和MSC细胞，所述DC细胞和CIK细胞为自体细胞，所述MSC细胞为同种异体细胞,且所述DC细胞携带IgE的CH3蛋白片段，携带方式为在DC细胞中加入IgE的CH3蛋白片段。
2.一种细胞治疗组合物的制备方法，其特征在于，包括以下步骤：
（1）自体外周血单个核细胞的制备；
（2）DC细胞的分离和培养；
（3）CIK细胞的诱导培养；
（4）DC细胞中加入IgE的CH3蛋白片段，制备IgE(CH3) DC细胞；
（5）IgE(CH3) DC细胞与CIK细胞共培养，制备IgE(CH3) DC-CIK细胞；
（6）IgE(CH3) DC-CIK细胞与同种异体MSC细胞共培养制备细胞治疗组合物。
3.如权利要求2所述的一种细胞治疗组合物的制备方法，其特征在于，步骤（4）中，所述CH3蛋白片段的浓度为50ug-500ug/1×107DC细胞。
4.如权利要求2所述的一种细胞治疗组合物的制备方法，其特征在于，步骤（4）中，所述CH3蛋白片段采用真核细胞基因表达得到。
5.如权利要求2所述的一种细胞治疗组合物的制备方法，其特征在于，步骤（5）中，IgE(CH3) DC细胞与CIK细胞按照1:3-5的细胞数量比例混合共培养。
6.如权利要求2所述的一种细胞治疗组合物的制备方法，其特征在于，步骤（6）中，MSC细胞与IgE(CH3) DC-CIK细胞按照1:10-50的细胞数量比例混合共培养。
7.如权利要求2中所述的IgE(CH3) DC-CIK细胞与MSC细胞共培养得到的细胞治疗组合物在制备用于治疗过敏性反应的细胞类药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110722210.1A CN113403274B (zh) | 2021-06-28 | 2021-06-28 | 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110722210.1A CN113403274B (zh) | 2021-06-28 | 2021-06-28 | 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113403274A CN113403274A (zh) | 2021-09-17 |
| CN113403274B true CN113403274B (zh) | 2023-11-10 |
Family
ID=77679866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110722210.1A Active CN113403274B (zh) | 2021-06-28 | 2021-06-28 | 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113403274B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012009581A2 (en) * | 2010-07-14 | 2012-01-19 | University Of Southern California | Pharmaceutical compositions comprising gingiva-derived mesenchymal stem cells and methods of treating inflammation, wound healing and contact hypersensitivity |
| CA3055202A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Cd19 compositions and methods for immunotherapy |
| WO2018208067A1 (ko) * | 2017-05-08 | 2018-11-15 | 주식회사 툴젠 | 인위적으로 조작된 조작면역세포 |
| CN109535241A (zh) * | 2018-12-18 | 2019-03-29 | 北昊干细胞与再生医学研究院有限公司 | Dc-cik共培养细胞及其制备方法、致敏抗原和应用 |
| WO2021081115A1 (en) * | 2019-10-22 | 2021-04-29 | Alloplex Biotherapeutics | Compositions and methods for in vitro activation and expansion of serial killer t cell populations and passive immunization of a cancer patient with tumor cell killing cells |
-
2021
- 2021-06-28 CN CN202110722210.1A patent/CN113403274B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012009581A2 (en) * | 2010-07-14 | 2012-01-19 | University Of Southern California | Pharmaceutical compositions comprising gingiva-derived mesenchymal stem cells and methods of treating inflammation, wound healing and contact hypersensitivity |
| CA3055202A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Cd19 compositions and methods for immunotherapy |
| WO2018208067A1 (ko) * | 2017-05-08 | 2018-11-15 | 주식회사 툴젠 | 인위적으로 조작된 조작면역세포 |
| CN109535241A (zh) * | 2018-12-18 | 2019-03-29 | 北昊干细胞与再生医学研究院有限公司 | Dc-cik共培养细胞及其制备方法、致敏抗原和应用 |
| WO2021081115A1 (en) * | 2019-10-22 | 2021-04-29 | Alloplex Biotherapeutics | Compositions and methods for in vitro activation and expansion of serial killer t cell populations and passive immunization of a cancer patient with tumor cell killing cells |
Non-Patent Citations (6)
| Title |
|---|
| "Calculational and experimental investigations of the pressure effects on radical-radical cross combination reactions: C2H5+C2H3";Fahr 等;《J Phys Chem A》;第111卷(第29期);6600-9 * |
| "Human mesenchymal stem cells modulate allogeneic immune cell responses";Aggarwal 等;《BLOOD》;第105卷(第4期);1815-1822 * |
| "Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation";Spaggiari 等;《 BLOOD》;第107卷(第4期);1484-1490 * |
| "梧桐花粉致敏大鼠动物模型的建立及特异性抗体检测";陈小东 等;《细胞生物学杂志》(第5期);523-525 * |
| "脐血与外周血来源CIK治疗晚期结直肠癌的比较研究";张闯 等;《甘肃医药》;第40卷(第4期);336-339+342 * |
| "靶向GPC3的CAR-NK细胞在肝细胞肝癌免疫治疗中的研究";郭猛;《中国博士学位论文全文数据库 医药卫生科技辑》(第11期);E072-38 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113403274A (zh) | 2021-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100514957B1 (ko) | 수지상세포자극인자 | |
| WO2023011489A1 (zh) | 一种基因修饰干细胞及其用途 | |
| JP6592551B2 (ja) | 免疫調節活性を有する細胞集団、その調製方法、及び、その使用 | |
| CN105154395A (zh) | 一种增强MSCs免疫调节功能的临床级别细胞制备方法 | |
| US20160120910A1 (en) | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof | |
| CN105296431A (zh) | 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途 | |
| Pullarkat et al. | Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells | |
| JP5856025B2 (ja) | 単球またはｎｋ細胞を入手する方法 | |
| CN112626027A (zh) | 一种Treg细胞培养方法 | |
| CN110195042B (zh) | 一种树突状细胞的制备方法及应用 | |
| CN114507640B (zh) | 一种高增殖能力和高细胞毒性cik细胞的培养方法及其应用 | |
| US9410143B1 (en) | Biological molecules produced by electromagnetically stimulating living mammalian cells | |
| CN113403274B (zh) | 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用 | |
| CN112662625A (zh) | 一种t细胞培养基及其用于t细胞的扩增培养方法 | |
| CN112915199A (zh) | 一种负载热休克蛋白的异体mRNA-DC肿瘤疫苗及其制备方法和应用 | |
| CN105106237A (zh) | 一种高效杀伤肿瘤细胞生物制剂 | |
| CN115896016B (zh) | 培养组合物及其在培养免疫细胞中的应用 | |
| CN104998260A (zh) | 基于dc细胞的hpv病毒疫苗的制备方法 | |
| CN113980896B (zh) | Irf1在调控间充质干细胞免疫调节作用及产品上的应用 | |
| CN116286638A (zh) | 促进cd34+细胞向cd16+巨噬细胞分化并向m2极化的方法 | |
| CN114085812A (zh) | 一种高表达cd106和/或cd142表达降低的间充质干细胞群、其制备方法及应用 | |
| Cutler | A growth inhibitor from young expanding tobacco leaves | |
| CN108251370B (zh) | 非细胞来源的多肽致敏的dc-cik细胞、其构建方法及应用 | |
| Hu et al. | Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice | |
| CN114517181B (zh) | 一种人t淋巴细胞无血清培养基及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |